I would be disappointed to have missed out on the
Post# of 36514
From the PR on 12/31:
With an impending IND submission for Phase I and II human clinical trials to evaluate safety and
immunogenicity of the Ii-Key vaccine, NGIO is exploring additional opportunities to deploy the
targeted Ii-Key COVID-19 vaccine as a universal booster for RNA, DNA, and inactivated virus
vaccines that contain the entire spike protein and have the potential to elicit off-target and overactive immune responses.
You might want to add this site to your favorites. Studies get listed here:
https://clinicaltrials.gov/ct2/home
![Like This Post](/images/thumb-up.png)
![Dislike This Post](/images/thumb-down.png)